Technetium tc 99m albumin aggregated
As of the edition of 20 October 2026, Technetium tc 99m albumin aggregated is a protein: marketed, first approved in 1976 (US); US protection ended in 1988.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1976
- Kind
- Protein
- Brand name
- Macrotec
- First approved
- 23 February 1976 (US)
- Approvals on record
- 14 in 1 region
- Holder of the most recent approval
- Cis Bio; 8 holders in all
- Registered trials
- 1, 1 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
US protection ended in 1988.
US protection ended in 1988, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bracco Diagnostics. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Draximage | Later holder | 1987 to now |
| Jubilant DraxImage | Acquired holder | 2014 to now |
| Bracco Diagnostics | Later holder | |
| Byk-Mallinckrodt CIL | Later holder | |
| GE Healthcare | Later holder | |
| Pharmalucence | Earlier holder |